News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy


5/1/2012 10:13:25 AM

NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that patient enrollment has been completed in the Company's pivotal Phase 3 clinical trial of its proprietary oral testosterone (T) replacement product (CLR-610). Primary endpoint of the ongoing study is the percentage of men who achieve normal serum T levels after administration of CLR-610 for 90 days. In addition, safety and tolerability will be assessed.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES